Feasibility and efficacy of MEMMAT-like regimen in heavily pretreated adult patients with recurrent malignant embryonal brain tumors: A series of 6 cases
Open Access
- 6 January 2025
- journal article
- Published by Oxford University Press (OUP) in Neuro-Oncology Advances
- Vol. 7 (1) , vdaf071
Abstract
Background: The prognosis of adult patients with recurrent malignant embryonal brain tumors remains poor due to the lack of effective and validated treatment. A metronomic and antiangiogenic chemotherapy regimen called MEMMAT was developed in children, with promising results. Additional data on feasibility, tolerance, and efficacy in adults are necessary. Methods: This retrospective observational case series included adult patients with relapsing medulloblastoma (MB) or pineoblastoma (PB) treated with MEMMAT-adapted protocol. Treatment consisted of daily oral thalidomide, fenofibrate, and celecoxib, and alternating 21-day cycles of metronomic etoposide and cyclophosphamide associated with bevacizumab and personalized intraventricular chemotherapy. Results: Four SHH-activated MB and 2 PB were included. Median duration of treatment was 12 months (range 3–21). Significant partial response occurred in 2/4 MB patients and 2/2 PB. The best responses were observed on leptomeningeal lesions. Main grade 3–4 toxicity was neutropenia in all patients (no febrile neutropenia) and lymphopenia in all but one (2 opportunistic infections). Dose adjustments in chemotherapy and thalidomide for hematotoxicity were necessary in all patients within the first 3 months. Cumulative neurotoxicity from thalidomide affected the 4 patients with prolonged treatment (1 grade 3, 3 grade 2). Rechallenge was tried in PB patients and successful (duration: 9 months). Conclusions: MEMMAT is feasible in adult patients and can lead to a significant and sustained response in recurrent malignant embryonal brain tumors. Hematotoxicity is progressive and manageable. The withdrawal of thalidomide and starting dose adjustments on chemotherapy might be discussed.Keywords
This publication has 21 references indexed in Scilit:
- A phase II trial of a multi‐agent oral antiangiogenic (metronomic) regimen in children with recurrent or progressive cancerPediatric Blood & Cancer, 2013
- Molecular subgroups of medulloblastomaExpert Review of Neurotherapeutics, 2012
- Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomasActa Neuropathologica, 2012
- Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumorsPediatric Blood & Cancer, 2011
- Adult Medulloblastoma Comprises Three Major Molecular VariantsJournal of Clinical Oncology, 2011
- Pediatric and adult sonic hedgehog medulloblastomas are clinically and molecularly distinctActa Neuropathologica, 2011
- Preponderance of sonic hedgehog pathway activation characterizes adult medulloblastomaActa Neuropathologica, 2010
- A Feasibility Trial of Antiangiogenic (Metronomic) Chemotherapy in Pediatric Patients With Recurrent or Progressive CancerJournal of Pediatric Hematology/Oncology, 2005
- Epidemiology of adult medulloblastomaInternational Journal of Cancer, 1999
- An Operative Staging System and a Megavoltage Radiotherapeutic Technic for Cerebellar MedulloblastomasRadiology, 1969